Veeraswamy Seshiah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Veeraswamy Seshiah has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh Jain
Jain hospital & research centre, Kanpur, India
7 shared publications Vijayam Balaji
Dr. V. Balaji Diabetes Care Center and Dr. V. Seshiah Research Institute, Chennai, Tamil Nadu, India
6 shared publicationsAnil Kapur
World Diabetes Foundation, Gentofte, Denmark
5 shared publicationsHema Divakar
Divakar’s Specialty Hospital, Bengaluru, India
4 shared publicationsMadhuri S. Balaji
Diabetes Care and Research Institute, Chennai, Tamilnadu, India
4 shared publications- Anil Kapur
World Diabetes Foundation, Gentofte, Denmark
3 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
Prevention of GDM by treating early gestational glucose intolerance with and without metformin: a randomized controlled trial
- 1 August 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
Open AccessPrevention of GDM by treating early gestational glucose intolerance with and without metformin: a randomized controlled trial
- Open Access
- 4 March 2025
- Published by IntechOpen
Hope and Scope for Diabetes-Free Generations
Gestational diabetes mellitus (GDM) is a growing global health concern linked to the rising prevalence of obesity and type 2 diabetes. It poses significant short-term and long-term risks for both mothers and their offspring. This comprehensive review explores the concept of early gestational glucose intolerance (EGGI), emphasizing the importance of early detection and intervention to prevent GDM and its adverse outcomes and scope for Diabetes Free Generation. The fuel-mediated teratogenesis hypothesis explains how maternal hyperglycemia disrupts fetal development, leading to macrosomia, neonatal hypoglycemia, and long-term metabolic dysfunction. Early prediction through first-trimester postprandial blood glucose (PPBG) testing allows for timely intervention and management. Recent studies demonstrated the high predictive value of PPBG testing, emphasizing the potential for early identification of women at risk for GDM. Effective management strategies include medical nutrition therapy, exercise, and pharmacological interventions like metformin, particularly when initiated early in pregnancy. The successful intervention program at Chennai and Delhi highlights the efficacy of early detection and proactive management in reducing adverse outcomes. Primordial prevention, focusing on preconception care and early pregnancy screening, is crucial for breaking the cycle of transgenerational transmission of metabolic disorders. By addressing risk factors before and during pregnancy, we can create a healthier future for both mothers and their children. Continued research is needed to validate GDM prevention and management.
- 4 March 2025
- Published by IntechOpen
Open AccessHope and Scope for Diabetes-Free Generations
Gestational diabetes mellitus (GDM) is a growing global health concern linked to the rising prevalence of obesity and type 2 diabetes. It poses significant short-term and long-term risks for both mothers and their offspring. This comprehensive review explores the concept of early gestational glucose intolerance (EGGI), emphasizing the importance of early detection and intervention to prevent GDM and its adverse outcomes and scope for Diabetes Free Generation. The fuel-mediated teratogenesis hypothesis explains how maternal hyperglycemia disrupts fetal development, leading to macrosomia, neonatal hypoglycemia, and long-term metabolic dysfunction. Early prediction through first-trimester postprandial blood glucose (PPBG) testing allows for timely intervention and management. Recent studies demonstrated the high predictive value of PPBG testing, emphasizing the potential for early identification of women at risk for GDM. Effective management strategies include medical nutrition therapy, exercise, and pharmacological interventions like metformin, particularly when initiated early in pregnancy. The successful intervention program at Chennai and Delhi highlights the efficacy of early detection and proactive management in reducing adverse outcomes. Primordial prevention, focusing on preconception care and early pregnancy screening, is crucial for breaking the cycle of transgenerational transmission of metabolic disorders. By addressing risk factors before and during pregnancy, we can create a healthier future for both mothers and their children. Continued research is needed to validate GDM prevention and management.
- 15 July 2023
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 43 (4) , 483-484
Primordial prevention: a futuristic approach to intervene in gestational diabetes and its sequelae
- 15 July 2023
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 43 (4) , 483-484
Primordial prevention: a futuristic approach to intervene in gestational diabetes and its sequelae
- Open Access
- 15 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32573
Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our patients with type 2 diabetes on Remogliflozin, a type of SGLT2 inhibitor approved in India for the treatment of diabetes, seems to cause acute tubular necrosis as confirmed by clinical and pathological evidence in our study. The two critical findings in our research include a consistent rise in hs-CRP and a pathologist's biopsy report, excluding other causes. Therefore, we need sizeable cardiovascular-renal outcome trials to ascertain the safety of Remogliflozin in future studies.
- 15 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32573
Open AccessUse of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our patients with type 2 diabetes on Remogliflozin, a type of SGLT2 inhibitor approved in India for the treatment of diabetes, seems to cause acute tubular necrosis as confirmed by clinical and pathological evidence in our study. The two critical findings in our research include a consistent rise in hs-CRP and a pathologist's biopsy report, excluding other causes. Therefore, we need sizeable cardiovascular-renal outcome trials to ascertain the safety of Remogliflozin in future studies.
- 28 November 2021
- Published by Morressier GmbH
Puzzle and Muddle in the Guidelines for Diagnosing Gestational Diabetes Mellitus-Efforts to Solve
- 28 November 2021
- Published by Morressier GmbH
Puzzle and Muddle in the Guidelines for Diagnosing Gestational Diabetes Mellitus-Efforts to Solve
- 28 November 2021
- Published by Morressier GmbH
Covid19 toe, a late manifestation of mild SARS-CoV-2 with Diabetes
- 28 November 2021
- Published by Morressier GmbH
Covid19 toe, a late manifestation of mild SARS-CoV-2 with Diabetes
- 28 November 2021
- Published by Morressier GmbH
Focus on Foetus for Future: GDM is the Mother of NCDs
- Open Access
- 1 June 2021
- Published by Georg Thieme Verlag KG in Journal of Social Health and Diabetes
- Vol. 9 (01) , e1-e7
Advantages of Screening for Glucose Tolerance in the Sequential Weeks of Gestation
Prelife exposure relates to development during the time preceding the first appearance of life, a time course from “conception to confinement.” From single cell zygote to finally formed fetus at confinement, a remarkable change occurs due to maternal fuels and hormonal influence on the fetal development. The crucial period in the fetal development is the first trimester. Early exposure to aberrant maternal metabolism in the embryonic developmental stage would result in congenital malformation and fetal wastage. Maintaining maternal glucose at the recommended level of fasting 80 to 90 mg and 2 hours postprandial plasma glucose 110 to 120 mg/dL during preconceptional period and throughout pregnancy is the assurance for the healthy offspring with ideal birth weight of 2.5 to 3.5 kg and prevention of noncommunicable diseases in the future.
- 1 June 2021
- Published by Georg Thieme Verlag KG in Journal of Social Health and Diabetes
- Vol. 9 (01) , e1-e7
Open AccessAdvantages of Screening for Glucose Tolerance in the Sequential Weeks of Gestation
Prelife exposure relates to development during the time preceding the first appearance of life, a time course from “conception to confinement.” From single cell zygote to finally formed fetus at confinement, a remarkable change occurs due to maternal fuels and hormonal influence on the fetal development. The crucial period in the fetal development is the first trimester. Early exposure to aberrant maternal metabolism in the embryonic developmental stage would result in congenital malformation and fetal wastage. Maintaining maternal glucose at the recommended level of fasting 80 to 90 mg and 2 hours postprandial plasma glucose 110 to 120 mg/dL during preconceptional period and throughout pregnancy is the assurance for the healthy offspring with ideal birth weight of 2.5 to 3.5 kg and prevention of noncommunicable diseases in the future.
- 9 September 2020
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 40 (3) , 329-334
Diagnosis and principles of management of gestational diabetes mellitus in the prevailing COVID-19 pandemic
Background Limited medical facilities are available due to Covid-19 pandemic. Nevertheless, all efforts should be made in planning judicial and possible methods of delivering health care, particularly to pregnant woman with GDM. GDM may play a crucial role in the increasing prevalence of diabetes and obesity and also may be the origin of cardiometabolic diseases. Methods It is mandatary to diagnose and care pregnant woman with GDM. The test suggested to diagnose GDM has to be evidence based and in this regard “a single test procedure” evaluated meets this requirement. This doable test has been accepted by the Diabetes in Pregnancy Study Group India (DIPSI) and approved by MHFW-GOI, WHO, International Diabetes Federation, and International Federation of Obstetricians and Gynecologists. MHFW-GOI also recommends testing at first antenatal visit and then at 24–28 weeks of gestation. This opportunity can also be utilized for performing ultrasonography for assessing fetal development. Result The first-line management is MNT and life style modifications. Non-responders may require insulin or OHA. The target glycemic control is FPG ~ 5.0 mmol/dl (90 mg/dl) and 2 h PPPG ~ 6.7 mmol/dl (120 mg/dl). The goal is to obtain newborns birth weight appropriate for gestational age between 2.5 and 3.5 kg, a step to prevent offspring developing diabetes. Conclusion The essential precaution required during COVID pandemic is to wear face mask, avoid crowded places, and maintain social distancing. Finally, the economical and evidence based “single test procedure” of DIPSI is most appropriate for screening during the COVID pandemic.
- 9 September 2020
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 40 (3) , 329-334
Diagnosis and principles of management of gestational diabetes mellitus in the prevailing COVID-19 pandemic
Background Limited medical facilities are available due to Covid-19 pandemic. Nevertheless, all efforts should be made in planning judicial and possible methods of delivering health care, particularly to pregnant woman with GDM. GDM may play a crucial role in the increasing prevalence of diabetes and obesity and also may be the origin of cardiometabolic diseases. Methods It is mandatary to diagnose and care pregnant woman with GDM. The test suggested to diagnose GDM has to be evidence based and in this regard “a single test procedure” evaluated meets this requirement. This doable test has been accepted by the Diabetes in Pregnancy Study Group India (DIPSI) and approved by MHFW-GOI, WHO, International Diabetes Federation, and International Federation of Obstetricians and Gynecologists. MHFW-GOI also recommends testing at first antenatal visit and then at 24–28 weeks of gestation. This opportunity can also be utilized for performing ultrasonography for assessing fetal development. Result The first-line management is MNT and life style modifications. Non-responders may require insulin or OHA. The target glycemic control is FPG ~ 5.0 mmol/dl (90 mg/dl) and 2 h PPPG ~ 6.7 mmol/dl (120 mg/dl). The goal is to obtain newborns birth weight appropriate for gestational age between 2.5 and 3.5 kg, a step to prevent offspring developing diabetes. Conclusion The essential precaution required during COVID pandemic is to wear face mask, avoid crowded places, and maintain social distancing. Finally, the economical and evidence based “single test procedure” of DIPSI is most appropriate for screening during the COVID pandemic.
- Open Access
- 28 April 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (9) , 3062
“If I Don’t Eat Enough, I Won’t Be Healthy”. Women’s Experiences with Gestational Diabetes Mellitus Treatment in Rural and Urban South India
Gestational diabetes mellitus (GDM) is associated with a range of adverse pregnancy outcomes as well as increased risk of future type 2 diabetes and cardiovascular disease. In India, 10%–35% of pregnant women develop GDM. In this study, we investigated women’s experiences with the dietary and pharmaceutical treatment for GDM in rural and urban Tamil Nadu, India. Semi-structured interviews were conducted with 19 women diagnosed with GDM. Data were analyzed using qualitative content analysis. Three overall aspects were discovered with several sub-aspects characterizing women’s experiences: emotional challenges (fear and apprehension for the baby’ health and struggling to accept a treatment seen as counterintuitive to being safe and healthy), interpersonal challenges (managing treatment in the near social relations and social support, and coordinating treatment with work and social life), and health system-related challenges (availability and cost of treatment, interaction with health care providers). Some aspects acted as barriers. However, social support and positive, high-quality interactions with health care providers could mitigate some of these barriers and facilitate the treatment process. Greater efforts at awareness creation in the social environment and systemic adjustments in care delivery targeting the individual, family, community and health system levels are needed in order to ensure that women with GDM have the opportunity to access treatment and are enabled and motivated to follow it as well.
- 28 April 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (9) , 3062
Open Access“If I Don’t Eat Enough, I Won’t Be Healthy”. Women’s Experiences with Gestational Diabetes Mellitus Treatment in Rural and Urban South India
Gestational diabetes mellitus (GDM) is associated with a range of adverse pregnancy outcomes as well as increased risk of future type 2 diabetes and cardiovascular disease. In India, 10%–35% of pregnant women develop GDM. In this study, we investigated women’s experiences with the dietary and pharmaceutical treatment for GDM in rural and urban Tamil Nadu, India. Semi-structured interviews were conducted with 19 women diagnosed with GDM. Data were analyzed using qualitative content analysis. Three overall aspects were discovered with several sub-aspects characterizing women’s experiences: emotional challenges (fear and apprehension for the baby’ health and struggling to accept a treatment seen as counterintuitive to being safe and healthy), interpersonal challenges (managing treatment in the near social relations and social support, and coordinating treatment with work and social life), and health system-related challenges (availability and cost of treatment, interaction with health care providers). Some aspects acted as barriers. However, social support and positive, high-quality interactions with health care providers could mitigate some of these barriers and facilitate the treatment process. Greater efforts at awareness creation in the social environment and systemic adjustments in care delivery targeting the individual, family, community and health system levels are needed in order to ensure that women with GDM have the opportunity to access treatment and are enabled and motivated to follow it as well.